HBV/HCV相关性肝细胞癌抗病毒治疗专家建议

中华医学会肝病学分会肝癌学组

HBV/HCV相关性肝细胞癌抗病毒治疗专家建议

中华医学会肝病学分会肝癌学组

基金项目:

国家科技重大专项“艾滋病和病毒性肝炎等重大传染病防治”课题(2012ZX10002-016)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 4093
- HTML全文浏览量: 5
- PDF下载量: 1237
- 被引次数: 0
出版历程
- 出版日期: 2013-01-20

Recommendation on antiviral therapy to hepatitis B/C virus related hepatocellular carcinoma

Liver Cancer Study Group，Chinese Society of Hepatology，Chinese Medical Association

Research funding:

摘要

摘要:
<正>乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染在肝细胞癌(HCC)的发生发展中起重要作用。我国近年发布的《慢性乙型肝炎防治指南(2010版)》和《原发性肝癌诊疗规范(2011版)》都强调了肝癌患者抗病毒治疗的重要性,但未作深入具体阐述。《丙型肝炎防治指南(2004版)》也注意到抗病毒治疗延缓HCC的发生。
- 肝炎,乙型 /
- 肝炎,丙型 /
- 肝肿瘤 /
- 治疗 /
- 指南
- hepatitis B /
- hepatitis C /
- liver neoplasms /
- therapy /
- guidebooks

HTML全文

参考文献(35)

[1]Sun CA, Wu DM, Lin CC, et al.Incidence and cofactors ofhepatitis C virus-related hepatocellular carcinoma:a pro-spective study of 12, 008 men in Taiwan[J].Am J Epidemi-ol, 2003, 157 (8) :674-682.

[2]Chen CJ, Yang HI, Su J, et al.Risk of hepatocellular carci-noma across a biological gradient of serum hepatitis B virusDNA level[J].JAMA, 2006, 295 (1) :65-73.

[3]El-Serag HB.Epidemiology of viral hepatitis and hepatocellularcarcinoma[J].Gastroenterology, 2012, 142 (6) :1264-1273.

[4]Ishikawa T.Clinical features of hepatitis B virus-related hep-atocellular carcinoma[J].World J Gastroenterol, 2010, 16 (20) :2463-2467.

[5]Xu B, Hu DC, Rosenberg DM, et al.Chronic hepatitis B:along-term retrospective cohort study of disease progressionin Shanghai, China[J].J Gastroenterol Hepatol, 2003, 18 (12) :1345-1352.

[6]Fattovich G, Bortolotti F, Donato F.Natural history of chronichepatitis B:special emphasis on disease progression andprognostic factors[J].J Hepatol, 2008, 48 (2) :335-52.

[7]Bruix J, Sherman M.Management of hepatocellular carcinoma:an update[J].Hepatology, 2011, 53 (3) :1020-1022.

[8]Wu JC, Huang YH, Chau GY, et al.Risk factors for earlyand late recurrence in hepatitis B-related hepatocellular car-cinoma[J].J Hepatol, 2009, 51 (5) :890-897.

[9]Lok ASF.Does antiviral therapy prevent recurrence of hepati-tis B virus-related hepatocellular carcinoma after curative liv-er resection[J].JAMA, 2012, 308 (18) :1922-1924.

[10]Chen CJ, Yang HI, Iloeje UH.Hepatitis B virus DNA levelsand outcomes in chronic hepatitis B[J].Hepatology, 2009, 49 (5 Suppl) :S72-S84.

[11]Kubo S, Nishiguchi S, Shuto T, et al.Effects of continuoushepatitis with persistent hepatitis C viremia on outcome afterresection of hepatocellular carcinoma[J].Jpn J Cancer Res, 1999, 90 (2) :162-170.

[12]Shindoh J, Hasegawa K, Matsuyama Y, et al.Low hepatitisC viral load predicts better long-term outcomes in patientsundergoing resection of hepatocellular carcinoma irrespectiveof serologic eradication of hepatitis C virus[J].J Clin Oncol, 2012, Nov 5.doi: 10.1200/JCO.2012.44.3234.

[13]Chan ACY, Chok KSH, Yuen WK, et al.Impact of antiviraltherapy on the survival of patients after major hepatectomyfor hepatitis B virus-related hepatocellular carcinoma[J].Arch Surg, 2011, 146 (6) :675-681.

[14]Wu CY, Chen YJ, Ho HJ, et al.Association between nucle-oside analogues and risk of hepatitis B virus-related hepato-cellular carcinoma recurrence following liver resection[J].JAMA, 2012, 308 (18) :1906-1913.

[15]Jang JW, Choi JY, Bae SH, et al.A randomized controlledstudy of preemptive lamivudine in patients receiving transarteri-al chemo lipiodolization[J].Hepatology, 2006, 43:233-240.

[16]Koda M, Nagahara T, Matono T, et al.Nucleotide analogsfor patients with HBV-related hepatocellular carcinoma in-crease the survival rate through improved liver function[J].Inter Med, 2009, 48 (1) :11-17.

[17]Cheng SQ, Wu MC, Cao H, et al.Antiviral therapy usinglamivudine and thymosin alpha 1 for hepatocellular carcinomacoexisting with chronic hepatitis B infection[J].Hepatogas-troenterology, 2006, 53 (68) :249-252.

[18]Wong JS, Wong GL, Tsoi KK, et al.Meta-analysis:the ef-ficacy of anti-viral therapy in prevention of recurrence aftercurative treatment of chronic hepatitis B-related hepatocel-lular carcinoma[J].Aliment Pharmacol Ther, 2011, 33 (10) :1104-1112.

[19]Sun HC, Tang ZY, Wang L, et al.Postoperative interferonalpha treatment postponed recurrence and improved overallsurvival in patients after curative resection of HBV-relatedhepatocellular carcinoma:a randomized clinical trial[J].JCancer Res Clin Oncol, 2006, 132 (7) :458-465.

[20]Lo CM, Liu CL, Chan SC, et al.A randomized, controlledtrial of postoperative adjuvant interferon therapy after resec-tion of hepatocellular carcinoma[J].Ann Surg, 2007, 245 (6) :831-842.

[21]Liaw YF, Sung JJ, Chow WC, et al.Lamivudine for patientswith chronic hepatitis B and advanced liver disease[J].NEngl J Med, 2004, 351 (15) :1521-1531.

[22] 许蓓, 徐国光, 郭清, 等.拉米夫定对慢性乙型肝炎伴重度肝纤维化患者的长期应用疗效———NUCB4006十年随访研究[J].中华传染病杂志, 2010, 28 (11) :656-661.

[23]Sung JJ, Tsoi KK, Wong VW, et al.Meta-analysis:treatmentof hepatitis B infection reduces risk of hepatocellular carcinoma[J].Aliment Pharmacol Ther, 2008, 8 (9) :1067-1077.

[24]Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al.Incidence of hepatocellular carcinoma in chronic hepatitis Bpatients receiving nucleos (t) ide therapy:A systematic re-view[J].J Hepatol, 2010, 53 (2) :348-356.

[25]Tanimoto Y, Tashiro H, Aikata H, et al.Impact of pegylatedinterferon therapy on outcomes of patients with hepatitis Cvirus-related hepatocellular carcinoma after curative hepaticresection[J].Ann Surg Oncol, 2012, 19 (2) :418-425.

[26]Singal AK, Singh A, Jaganmohan S, et al.Antiviral therapyreduces risk of hepatocellular carcinoma in patients with hep-atitis C virus-related cirrhosis[J].Clin Gastroenterol Hepa-tol, 2010, 8 (2) :192-199.

[27]Miyake Y, Takaki A, Iwasaki Y, et al.Meta-analysis:inter-feron-alpha prevents the recurrence after curative treatmentof hepatitis C virus-related hepatocellular carcinoma[J].JViral Hepat, 2010, 17 (4) :287-292.

[28]Gonzalez SA.Management of recurrent hepatitis C followingliver transplantation[J].Gastroenterol Hepatol, 2010, 6 (10) :637-645.

[29]Akamatsu N, Sugawara Y.Liver transplantation and hepatitis C[J].Int J Hepatol, 2012 (2012) .doi: 10.1155/2012/686135.

[30]European Association for the Study of the Liver.EASL Clini-cal Practice Guidelines:management of hepatitis C virus in-fection[J].J Hepatol, 2011, 55 (2) :245-264.

[31]Yoshida H, Shiratori Y, Moriyama M, et al.Interferon therapy re-duces the risk for hepatocellular carcinoma:national surveillanceprogram of cirrhotic and noncirrhotic patients with chronic hepati-tis C in Japan[J].Ann Intern Med, 1999, 131 (1) :174-181.

[32]Watanabe S, Enomoto N, Koike K, et al.Cancer preventiveeffect of pegylated interferon a-2b plus ribavirin in a real-life clinical setting in Japan:PERFECT interim analysis[J].Hepatol Res, 2011, 41 (10) :955-964.

[33]Lok AS, Seeff LB, Morgan TR, et al.Incidence of hepato-cellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease[J].Gastroenterology, 2009, 136 (1) :138-148.

[34]Lok AS, Evehart JE, Wright EC, et al.Maintenance peginterfer-on therapy and other factors associated with hepatocellular car-cinoma in patients with advanced hepatitis C[J].Gastroenterol-ogy, 2011, 140 (3) :840-849.

[35] European Association For The Study of The Liver;European Or-ganisation For Research And Treatment of Cancer.EASL-EORTC Clinical Practice Guidelines:Management of hepatocel-lular carcinoma[J].J Hepatol, 2012, 56 (4) :908-943.

施引文献

资源附件(0)

访问统计